STOCK TITAN
  1. Home
  2. Sec-filings
  3. TKPHF
  4. [Form 4] TAKEDA PHARMACEUTICAL CO LTD Insider Trading Activity

Takeda (TAK) R&D chief awarded 212,470 ADS in performance RSU grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Plump Andrew Stewart reported acquisition or exercise transactions in this Form 4 filing.

Takeda Pharmaceutical Co. Ltd. director and President of R&D Andrew Stewart Plump reported a compensation-related equity award. On April 27, 2026, he was credited with 212,470 American Depositary Shares at $0.00 per share as a grant/award linked to earlier restricted stock units.

The award stems from RSUs originally granted on July 1, 2023, which vest in ADSs based on performance metrics including core revenue, core operating profit, and key R&D milestones. After the award, he directly holds 806,572 ADS and indirectly holds 281,307 ADS through a trust. The filing notes unvested RSUs scheduled to vest on July 1, 2026 (329,478 shares), July 1, 2027 (91,580 shares), and July 1, 2028 (43,374 shares), each representing a contingent right to receive one ADS.

Positive

  • None.

Negative

  • None.
Insider Plump Andrew Stewart
Role President, R&D
Type Security Shares Price Value
Grant/Award American Depositary Shares 212,470 $0.00 --
holding American Depositary Shares -- -- --
Holdings After Transaction: American Depositary Shares — 806,572 shares (Direct, null); American Depositary Shares — 281,307 shares (Indirect, By Trust)
Footnotes (1)
  1. On July 1, 2023, the reporting person was granted an award of restricted stock units (RSUs), which vest in the form of American Depositary Shares based upon the achievement of the specified performance metrics, including core revenue, core operating profit, and important R&D milestones. On April 27, 2026, the Compensation Committee of the Board of Directors determined the number of RSUs to be awarded based on these performance metrics, which amount is reported above. Includes 464.432 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest on the following schedule: July 1, 2026 (329,478 shares), July 1, 2027 (91,580 shares) and July 1, 2028 (43,374 shares).
Equity award 212,470 American Depositary Shares Grant/award acquisition on April 27, 2026
Award price $0.00 per share Compensation-related grant, not market purchase
Direct holdings after award 806,572 ADS Total direct ownership following April 27, 2026 transaction
Indirect holdings by trust 281,307 ADS Indirect ownership through a trust after reported transactions
RSUs vesting 2026 329,478 shares RSUs scheduled to vest on July 1, 2026
RSUs vesting 2027 91,580 shares RSUs scheduled to vest on July 1, 2027
RSUs vesting 2028 43,374 shares RSUs scheduled to vest on July 1, 2028
Original RSU grant date July 1, 2023 Date RSUs were originally granted subject to performance
restricted stock units (RSUs) financial
"the reporting person was granted an award of restricted stock units (RSUs)"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
American Depositary Shares financial
"which vest in the form of American Depositary Shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
core operating profit financial
"based upon the achievement of the specified performance metrics, including core revenue, core operating profit"
Core operating profit is the company's profit from its normal day-to-day business activities after removing one-time items, unusual gains or losses, and financing or tax effects. Investors use it like a household budget that strips out unexpected windfalls or repairs: it shows the steady earnings power of the business and helps compare performance across periods or with peers without distortion from rare or non‑operational events.
Compensation Committee financial
"the Compensation Committee of the Board of Directors determined the number of RSUs"
A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.
contingent right financial
"Each RSU represents a contingent right to receive one American Depositary Share."
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Plump Andrew Stewart
(Last)(First)(Middle)
300 MASSACHUSETTS AVE.
(Street)
CAMBRIDGE MASSACHUSETTS 02139
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President, R&D
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/27/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
American Depositary Shares04/27/2026A(1)212,470A$0806,572(2)D
American Depositary Shares281,307IBy Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. On July 1, 2023, the reporting person was granted an award of restricted stock units (RSUs), which vest in the form of American Depositary Shares based upon the achievement of the specified performance metrics, including core revenue, core operating profit, and important R&D milestones. On April 27, 2026, the Compensation Committee of the Board of Directors determined the number of RSUs to be awarded based on these performance metrics, which amount is reported above.
2. Includes 464.432 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest on the following schedule: July 1, 2026 (329,478 shares), July 1, 2027 (91,580 shares) and July 1, 2028 (43,374 shares).
Remarks:
/s/ Max Heuer, by power of attorney, for Andrew Plump04/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Takeda (TAK) report for Andrew Stewart Plump?

Takeda reported that Andrew Stewart Plump, President of R&D and director, received a grant of 212,470 American Depositary Shares as compensation. The award reflects performance-based restricted stock units granted in 2023, now converted into ADSs following achievement of specified metrics.

How many Takeda (TAK) shares did Andrew Stewart Plump receive in this Form 4 filing?

He received 212,470 American Depositary Shares at a reported price of $0.00 per share as a grant or award. This represents equity compensation rather than an open-market purchase, tied to performance-based restricted stock units granted earlier.

Were Andrew Stewart Plump’s Takeda (TAK) shares bought or awarded?

The shares were awarded, not bought. The Form 4 shows transaction code A, described as a grant, award, or other acquisition, with 212,470 American Depositary Shares credited at $0.00 per share as part of Takeda’s equity compensation program.

What performance metrics determined Andrew Stewart Plump’s Takeda (TAK) RSU award?

The RSU award was based on performance metrics including core revenue, core operating profit, and important R&D milestones. On April 27, 2026, Takeda’s Compensation Committee determined the number of RSUs to be awarded under these criteria, resulting in the 212,470 ADS grant.

How many Takeda (TAK) shares does Andrew Stewart Plump hold after this Form 4 event?

After the reported transactions, he directly holds 806,572 American Depositary Shares. In addition, 281,307 ADS are held indirectly through a trust, giving a substantial combined equity position associated with his role at Takeda.

What is the vesting schedule for Andrew Stewart Plump’s Takeda (TAK) RSUs?

Unvested RSUs are scheduled to vest as American Depositary Shares on three dates: July 1, 2026 (329,478 shares), July 1, 2027 (91,580 shares), and July 1, 2028 (43,374 shares). Each RSU represents a contingent right to receive one ADS upon vesting.